{"product_id":"adar-antibody-fitc-conjugated-cat-csb-pa001324lc01hu","title":"ADAR Antibody, FITC conjugated - Cat. #: CSB-PA001324LC01HU","description":"\u003cp\u003e\u003cb\u003eSize \u003c\/b\u003e:50ul\u003c\/p\u003e\u003cp\u003e\u003cb\u003eClone Number\u003c\/b\u003e:\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAliases\u003c\/b\u003e:136 kDa double-stranded RNA-binding protein antibody; 136kDa double stranded RNA binding protein antibody; Adar 1 antibody; ADAR antibody; Adar1 antibody; Adenosine deaminase acting on RNA 1 A antibody; Adenosine deaminase RNA specific 1 antibody; Adenosine deaminase RNA specific antibody; Adenosine deaminase that act on RNA antibody; AGS6 antibody; AV242451 antibody; Double stranded RNA specific adenosine deaminase antibody; Double-stranded RNA-specific adenosine deaminase antibody; Double-stranded RNA-specific editase Adar antibody; DRADA antibody; Dsh antibody; Dsrad antibody; DSRAD_HUMAN antibody; dsRNA adenosine deaminase antibody; EC 3.5.4.- antibody; G1P1 antibody; IFI 4 antibody; IFI-4 antibody; IFI4 antibody; Ifi4 protein antibody; Interferon induced protein 4 antibody; Interferon inducible protein 4 antibody; Interferon-inducible protein 4 antibody; K88DSRBP antibody; mZaADAR antibody; P136 antibody; Pre-mRNA adenosine deaminase antibody; RNA adenosine deaminase 1 antibody; RNA-editing deaminase 1 antibody; RNA-editing enzyme 1 antibody\u003c\/p\u003e\u003cp\u003e\u003cb\u003eProduct Type\u003c\/b\u003e:Polyclonal Antibody\u003c\/p\u003e\u003cp\u003e\u003cb\u003eImmunogen Species\u003c\/b\u003e:Homo sapiens (Human)\u003c\/p\u003e\u003cp\u003e\u003cb\u003eUniProt ID\u003c\/b\u003e:P55265\u003c\/p\u003e\u003cp\u003e\u003cb\u003eImmunogen\u003c\/b\u003e:Recombinant Human Double-stranded RNA-specific adenosine deaminase protein (367-471AA)\u003c\/p\u003e\u003cp\u003e\u003cb\u003eRaised in\u003c\/b\u003e:Rabbit\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSpecies Reactivity\u003c\/b\u003e:Human\u003c\/p\u003e\u003cp\u003e\u003cb\u003eTested Applications\u003c\/b\u003e:\u003c\/p\u003e\u003cp\u003e\u003cb\u003eBackground\u003c\/b\u003e:Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q\/R site, but edits efficiently at the R\/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2\/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5\\'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber\/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eClonality\u003c\/b\u003e:Polyclonal\u003c\/p\u003e\u003cp\u003e\u003cb\u003eIsotype\u003c\/b\u003e:IgG\u003c\/p\u003e\u003cp\u003e\u003cb\u003ePurification Method\u003c\/b\u003e:\u0026gt;95%, Protein G purified\u003c\/p\u003e\u003cp\u003e\u003cb\u003eConjugate\u003c\/b\u003e:FITC\u003c\/p\u003e\u003cp\u003e\u003cb\u003eBuffer\u003c\/b\u003e:Preservative: 0.03% Proclin 300\u003cbr\u003eConstituents: 50% Glycerol, 0.01M PBS, pH 7.4\u003c\/p\u003e\u003cp\u003e\u003cb\u003eForm\u003c\/b\u003e:Liquid\u003c\/p\u003e\u003cp\u003e\u003cb\u003eStroage\u003c\/b\u003e:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eTarget Names\u003c\/b\u003e:ADAR\u003c\/p\u003e\u003cp\u003e\u003cb\u003eResearch Areas\u003c\/b\u003e:Epigenetics and Nuclear Signaling; Microbiology\u003c\/p\u003e","brand":"Gene Bio Systems","offers":[{"title":"Default Title","offer_id":40487740670052,"sku":"CSB-PA001324LC01HU","price":287.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0558\/8588\/9636\/products\/no_image_default_image-jpeg_9fc1a2ed-0d1d-41e5-a790-e545a727f886.jpg?v=1660169861","url":"https:\/\/www.genebiosystems.com\/en-gb\/products\/adar-antibody-fitc-conjugated-cat-csb-pa001324lc01hu","provider":"GeneBio ","version":"1.0","type":"link"}